No black box warning on record for Xolremdi

As of the latest FDA labeling reviewed, Xolremdi (MAVORIXAFOR) does not carry a black box warning. Standard warnings and precautions still apply — see the full Xolremdi medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Embryo-fetal toxicity: Expected to cause fetal harm. Advise women of reproductive potential to use effective contraception. ( 5.1 , 8.1 , 8.3 ) QTc Interval Prolongation: : Correct any modifiable risk factors, assess QTc at baseline and monitor QTc during treatment as clinically indicated. XOLREMDI dose reduction or discontinuation may be required due to drug-drug intera

No black box warning on record for Xolremdi

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Embryo-fetal toxicity: Expected to cause fetal harm. Advise women of reproductive potential to use effective contraception. ( 5.1 , 8.1 , 8.3 ) QTc Interval Prolongation: : Correct any modifiable risk factors, assess QTc at baseline and monitor QTc during treatment as clinically indicated. XOLREMDI dose reduction or discontinuation may be required due to drug-drug intera

Xolremdi Black Box Warning

No black box warning on record for Xolremdi

Other warnings & precautions

Xolremdi Black Box Warning

No black box warning on record for Xolremdi

Other warnings & precautions